BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27806451)

  • 1. Medication selection and patient compliance in the clinical management of osteoporosis.
    Inderjeeth CA; Inderjeeth AJ; Raymond WD
    Aust Fam Physician; 2016 Nov; 45(11):814-817. PubMed ID: 27806451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to osteoporosis treatments: room for improvement.
    Warriner AH; Curtis JR
    Curr Opin Rheumatol; 2009 Jul; 21(4):356-62. PubMed ID: 19412103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
    Beard MK
    Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic therapy for the treatment and prevention of osteoporosis.
    McClung B; McClung M
    Nurs Clin North Am; 2001 Sep; 36(3):433-40, viii. PubMed ID: 11532658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
    Martens MG; Shaw H
    South Med J; 2008 Aug; 101(8):824-30. PubMed ID: 18622322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoporosis management: translating research into optimal fracture protection II.
    Singer AJ; Boonen S
    Curr Med Res Opin; 2008 Jun; 24(6):1789-96. PubMed ID: 18559165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
    Gold DT; Alexander IM; Ettinger MP
    Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for the prevention and treatment of osteoporosis.
    Maraka S; Kennel KA
    BMJ; 2015 Sep; 351():h3783. PubMed ID: 26333528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
    Emkey RD; Ettinger M
    Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of osteoporosis treatment on mortality: a meta-analysis.
    Bolland MJ; Grey AB; Gamble GD; Reid IR
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1174-81. PubMed ID: 20080842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
    Aspray TJ; Francis RM
    Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations regarding adherence of anti-osteoporosis therapy.
    Lagari VS; McAninch E; Baim S
    Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence.
    Rabenda V; Hiligsmann M; Reginster JY
    Expert Opin Pharmacother; 2009 Oct; 10(14):2303-15. PubMed ID: 19640210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient treatment preferences for osteoporosis.
    Fraenkel L; Gulanski B; Wittink D
    Arthritis Rheum; 2006 Oct; 55(5):729-35. PubMed ID: 17013870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
    Veszelyné Kotán E; Mészaros Á
    Acta Pharm Hung; 2016; 86(1):13-22. PubMed ID: 27295873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.